Celadon Pharmaceuticals Regulatory News (CEL)

28 Sep 2006 07:00

Celsis International PLC28 September 2006 CELSIS INTERNATIONAL PLC Pre-Close Trading Update 28 September 2006: Celsis International plc ("Celsis" or the "Company"), thelife sciences products and services company, today announces an update ontrading prior to the commencement of its close period. The Company has made good progress in the first half of the year, includingcompleting the acquisition of In Vitro Technologies Inc ("IVT"). Celsis is ontrack to announce strong organic revenue growth, plus additional incrementalgrowth from IVT, and solid profit results for the six months ended 30 September2006. The healthy growth at the Analytical Services division experienced in the secondhalf of last year has again been evident, as it continues its focus on customerdriven services. The Company expects this division to maintain its excellentgrowth into the second half of the financial year. The Rapid Detection business model is strong with the reagent business remainingrobust. Despite the temporary slow down in instrument sales, due to recentindustry consolidations and delayed capital spending, the division is nowshowing signs of a stronger second half. This division is also making progressin the pharmaceutical industry with recent regulatory approvals from the FDA,and demand from major customers accelerating. The integration of IVT is progressing to plan and the business is showing goodgrowth. The Analytical Services business development team have been trained tointroduce IVT's services to their pharmaceutical and biotechnology customer baseand as a result the breadth of Celsis' customer base is expanding. IVT remainsthe leader in its respective field of products and services to screen drugcompounds and we foresee rapid growth from this division. Celsis will announce its interim results for the six months ended 30 September2006 on Wednesday 8 November 2006. There will be a presentation to analysts onthe day at 9.30am, held at Financial Dynamics, Holborn Gate, 26 SouthamptonBuildings, London, WC2A 1PB. Jay LeCoque, Chief Executive Officer of Celsis, commented: "I am pleased to report that the Company is set to announce another strong setof results in this year's first half. We are encouraged with the performance ofour existing business and we still have continued growth and synergies from ouracquisition of IVT that have yet to be realised. "Celsis is well positioned for further growth in both revenue and profit and Iremain enthusiastic about the Company's prospects for the full year." Enquiries: Celsis International plc Tel: 01638 600 153Jay LeCoque, Chief Executive OfficerJenny Parsons, Corporate Communications Financial Dynamics Tel: 020 7831 3113Anna KeebleBen Atwell Notes to editors Celsis International plc Celsis International plc provides value enhancing products and services to thepharmaceutical, biopharmaceutical, and consumer products industries through itsthree business areas; rapid detection, analytical services and in vitrotechnologies. The company is listed on the London Stock Exchange (CEL.L). In addition to ensuring product quality and safety for consumers, each divisionhas the capacity to deliver substantial cost savings to Celsis' customers.Using proprietary technology, the rapid detection business is the world leaderin the provision of diagnostic systems for the rapid detection of contamination. By reducing the time it takes to test and release raw materials and finishedgoods to the market place, Celsis technology facilitates increased manufacturingproductivity and improved supply chain management. The analytical servicesdivision provides outsourced laboratory testing services to pharmaceutical andbiopharmaceutical companies to ensure the stability and chemical composition oftheir products. In Vitro Technologies (IVT) supplies in vitro testing productsand services to the pharmaceutical and biotechnology industries. IVT's in vitroproducts and services screen drug compounds early in the discovery process,thereby reducing the time and cost of drug development. Further information can be found on its website at www.celsis.com. This information is provided by RNS The company news service from the London Stock Exchange